Status:
COMPLETED
Roflumilast and Cognition
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Conditions:
Dementia
Eligibility:
All Genders
18-35 years
Phase:
PHASE2
Brief Summary
The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether ...
Eligibility Criteria
Inclusion
- 18 to 35 years of age
- Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected),
- Body mass index between 18.5 and 30
- Willingness to sign an informed consent.
- Positive evaluation on the memory screening
Exclusion
- History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness
- First-degree relative with psychiatric disorder (in particular major depressive disorder and suicidality)
- Excessive drinking (\>20 glasses of alcohol containing beverages per week)
- Pregnancy or lactation
- Use of chronic medication other than oral contraceptives
- Use of recreational drugs in the 2 weeks preceding participation
- Smoking
- Orthostatic hypotension
- Lactose intolerance
- Sensory or motor deficits which could reasonably be expected to affect test performance
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01433666
Start Date
September 1 2011
End Date
September 1 2013
Last Update
January 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University, Faculty of Psychology and Neuroscience
Maastricht, Limburg, Netherlands, 6200 MD